Recent insider trends for ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) have caught the attention of investors. Analysts study insider data to get a sense of sense of what key shareholders think about the outlook for a particular stock. In the case of IMUC, the data has some interesting implications for where the stock might be headed.
Institutions own 03.44% of ImmunoCellular Therapeutics, Ltd. (IMUC)’s shares. The total value of these holdings, in millions, is $0. Among active positions in the latest quarter, 8 holders increased their positions by a total of 911873 shares, 4 holders decreased the positions by a total of 28691 shares, and 8 holders held their positions. This works out to a net increase in ownership of 883182 shares, and suggests that institutions are feeling bullish about the stock.
Among new and sold out positions, 4 holders initiated new positions by a total of 132004 shares and 3 holders exited their positions by a total of 28074 shares. This nets out to an increase of 103930 shares and is a bullish sign for IMUC.
Insider ownership increased by a total of 0 shares, which suggests that IMUC’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: ownership increased by a net of 0 shares.
The analysis of insider buying and selling trends can be extended to the aggregate level. Short interest, which represents the number of a stock’s shares currently being shorted, captures what the market as a whole feels about a stock. ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)’s short interest is 2.4 million shares, or % of the float. This represents an increase of 6% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Insider data can help an investor form an outlook on a stock, but it’s important to supplement this data with other information such as technical indicators to form a more complete view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that IMUC is a Weak sell, which implies that IMUC is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) is overvalued.